We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HDL-Cholesterol Predicts Survival in Cirrhotic Patients with Gastrointestinal Bleeding

By LabMedica International staff writers
Posted on 10 Dec 2020
Image: Histopathology of a cirrhotic liver.  High-density lipoprotein cholesterol predicts survival in cirrhotic patients with acute gastrointestinal bleeding (Photo courtesy of Loyola University Chicago).
Image: Histopathology of a cirrhotic liver. High-density lipoprotein cholesterol predicts survival in cirrhotic patients with acute gastrointestinal bleeding (Photo courtesy of Loyola University Chicago).
Liver cirrhosis is an important cause of morbidity and mortality as a consequence of continuous liver injuries. Acute gastrointestinal bleeding is a serious complication and critical clinical event in cirrhotic patients. Hepatitis B virus (HBV) is the leading cause of liver cirrhosis in China.

Since the liver plays a crucial role in cholesterol homeostasis, hypercholesterolemia often occurs in patients with chronic liver diseases. The decrease in serum levels of lipids and lipoproteins is highly prevalent in cirrhotic patients, with a prevalence that increases in parallel with the disease severity.

Infectious disease specialists at the Peking University First Hospital (Beijing, China) evaluated from January 2008 to December 2015, consecutive cirrhotic patients with acute gastrointestinal bleeding who were randomly divided into the derivation (n = 629) and validation (n = 314) cohorts. Liver cirrhosis was confirmed either by liver biopsy or by clinical presentations, routine liver function tests and medical imaging techniques. A logistic regression model was established to confirm the association between lipoprotein cholesterol and mortality. Routine biochemical tests were performed in the hospital laboratory. Lipid profiles include triglyceride, cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).

The investigators reported that on ROC analysis, HDL-C showed excellent diagnostic accuracy for six-week mortality, with an area under the receiver operating characteristic curves (AUROC) of 0.847 (95% CI 0.789–0.905). The best cut-off value of HDL-C was 0.54 mmol/L, with a sensitivity of 85.1% and specificity of 74.2%. The laboratory variables significantly associated with 6-week mortality in the univariate analysis were as follows: hepatocellular carcinoma (HCC), packed red blood cells (PRBC) transfusion, hemoglobin (HGB), total leukocyte count (WBC), alanine aminotransferase (ALT), serum sodium (Na), total bilirubin (TBIL), albumin (ALB), cholesterol, HDL-C, LDL-C, serum creatinine (Scr), international normalized ratio (INR), fibrinogen (FIB). Multivariate logistic regression analyses showed that TBIL, HDL-C, Na, and HGB were independently associated with six-week mortality.

The authors concluded that HDL-C is a potential indicator for the prognosis of patients with cirrhosis and acute gastrointestinal bleeding. The new algorithm based on HDL-C allowed an accurate predictive assessment of 6-week mortality after bleeding attack. The study was published on November 16, 2020 in the journal BMC Gastroenterology.


Related Links:
Peking University First Hospital

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gastrointestinal Panel
Xpert® GI Panel
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more